Table 2. Baseline clinical and procedural characteristics by sex and randomized treatment assignment.
| Variables | Women (n = 795) | Men (n = 2,198) | ||||||
|---|---|---|---|---|---|---|---|---|
| P2Y12 inhibitor monotherapy (n = 408) | Dual antiplatelet therapy (n = 387) | P value | P2Y12 inhibitor monotherapy (n = 1,087) | Dual antiplatelet therapy (n = 1,111) | P value | |||
| Age, yr | 69.7 ± 9.3 | 69.7 ± 9.6 | 0.956 | 62.7 ± 10.6 | 62.5 ± 10.4 | 0.622 | ||
| ≥ 75 | 132 (32.4) | 140 (36.2) | 0.289 | 150 (13.8) | 150 (13.5) | 0.888 | ||
| Body-mass index, kg/m2 | 24.4 ± 3.3 | 24.3 ± 3.3 | 0.708 | 24.5 ± 3.0 | 24.8 ± 3.1 | 0.032 | ||
| Comorbidities | ||||||||
| Hypertension | 288 (70.8) | 274 (70.8) | > 0.999 | 633 (58.2) | 645 (58.1) | 0.967 | ||
| Diabetes mellitus | 179 (44.0) | 164 (42.4) | 0.701 | 391 (36.0) | 388 (34.9) | 0.617 | ||
| Dyslipidemia | 203 (50.0) | 201 (52.1) | 0.609 | 470 (43.3) | 478 (43.3) | > 0.999 | ||
| Current smoking | 26 (6.4) | 18 (4.7) | 0.370 | 398 (36.7) | 349 (31.5) | 0.011 | ||
| Previous revascularization | 34 (8.4) | 47 (12.1) | 0.100 | 138 (12.7) | 130 (11.7) | 0.512 | ||
| Previous stroke | 35 (8.6) | 27 (7.0) | 0.472 | 64 (5.9) | 75 (6.8) | 0.461 | ||
| Previous myocardial infarction | 13 (3.2) | 14 (3.6) | 0.894 | 49 (4.5) | 51 (4.6) | > 0.999 | ||
| Chronic renal failure | 7 (1.7) | 21 (5.4) | 0.008 | 37 (3.4) | 32 (2.9) | 0.561 | ||
| Left ventricular ejection fraction, % | 61.3 ± 10.8 | 60.9 ± 11.5 | 0.570 | 59.5 ± 10.8 | 59.6 ± 10.4 | 0.869 | ||
| Clinical presentation | ||||||||
| Stable angina | 167 (40.9) | 165 (42.6) | 0.678 | 458 (42.1) | 460 (41.5) | 0.789 | ||
| Unstable angina | 145 (35.5) | 136 (35.1) | 0.966 | 322 (29.6) | 355 (32.0) | 0.244 | ||
| Non–ST-segment elevation myocardial infarction | 57 (14.0) | 62 (16.0) | 0.477 | 182 (16.7) | 168 (15.1) | 0.336 | ||
| ST-segment elevation myocardial infarction | 39 (9.6) | 24 (6.2) | 0.105 | 125 (11.5) | 126 (11.4) | 0.972 | ||
| Transradial approach | 289 (70.8) | 269 (69.5) | 0.741 | 802 (73.8) | 822 (74.0) | 0.951 | ||
| Multiple vessels disease | 198 (48.5) | 181 (46.8) | 0.671 | 551 (50.7) | 553 (49.8) | 0.699 | ||
| No. of lesion treated | 1.4 (0.6) | 1.4 (0.6) | 0.787 | 1.4 (0.7) | 1.4 (0.7) | 0.385 | ||
| Location of lesions | ||||||||
| Left main | 2 (0.5) | 11 (2.8) | 0.020 | 21 (1.9) | 24 (2.2) | 0.820 | ||
| Left anterior descending artery | 263 (64.5) | 256 (66.1) | 0.670 | 640 (58.9) | 694 (62.5) | 0.093 | ||
| Left circumflex | 115 (28.2) | 90 (23.3) | 0.132 | 284 (26.1) | 286 (25.7) | 0.875 | ||
| Right coronary artery | 125 (30.6) | 126 (32.6) | 0.613 | 399 (36.7) | 398 (35.8) | 0.699 | ||
| Lesion complexity | ||||||||
| Calcified | 72 (17.6) | 60 (15.5) | 0.474 | 163 (15.0) | 169 (15.2) | 0.942 | ||
| Bifurcation | 45 (11.0) | 44 (11.4) | 0.969 | 154 (14.2) | 137 (12.3) | 0.221 | ||
| Thrombotic | 26 (6.4) | 18 (4.7) | 0.365 | 84 (7.7) | 94 (8.5) | 0.590 | ||
| Use of intravascular ultrasonography | 105 (25.9) | 94 (24.4) | 0.684 | 267 (24.6) | 312 (28.2) | 0.068 | ||
| Treated lesions per patient | 0.995 | 0.807 | ||||||
| 1 | 287 (70.3) | 269 (69.5) | 778 (71.6) | 772 (69.5) | ||||
| 2 | 98 (24.0) | 95 (24.5) | 231 (21.3) | 256 (23.0) | ||||
| 3 | 20 (4.9) | 20 (5.2) | 66 (6.1) | 71 (6.4) | ||||
| ≥ 4 | 3 (0.7) | 3 (0.8) | 12 (1.1) | 12 (1.1) | ||||
| Multilesion intervention | 121 (29.7) | 118 (30.5) | 0.858 | 309 (28.4) | 339 (30.5) | 0.305 | ||
| Multivessel intervention | 93 (22.8) | 92 (23.8) | 0.808 | 244 (22.4) | 276 (24.8) | 0.204 | ||
| No. of stents per patient | 0.753 | 0.355 | ||||||
| 1 | 261 (64.0) | 259 (67.1) | 721 (66.3) | 720 (64.8) | ||||
| 2 | 112 (27.5) | 98 (25.4) | 263 (24.2) | 277 (24.9) | ||||
| 3 | 27 (6.6) | 24 (6.2) | 75 (6.9) | 90 (8.1) | ||||
| ≥ 4 | 8 (2.0) | 5 (1.3) | 28 (2.6) | 20 (1.8) | ||||
| Stent length per patient, mm | 37.1 (21.0) | 36.4 (21.9) | 0.626 | 38.2 (23.2) | 38.4 (23.3) | 0.907 | ||
| Type of drug-eluting stents | 0.951 | 0.534 | ||||||
| Cobalt-chromium everolimus eluting | 136 (33.3) | 126 (32.6) | 389 (35.8) | 400 (36.0) | ||||
| Platinum-chromium everolimus eluting | 138 (33.8) | 130 (33.6) | 351 (32.3) | 348 (31.3) | ||||
| Sirolimus-eluting with biodegradable polymer | 134 (32.8) | 131 (33.9) | 347 (31.9) | 360 (32.4) | ||||
| Zotarolimus eluting | 0 | 0 | 0 | 1 (0.0) | ||||
| Paclitaxel-cilostazol eluting | 0 | 0 | 0 | 1 (0.0) | ||||
| Medications at discharge | ||||||||
| Aspirin | 406 (99.5) | 386 (99.7) | > 0.999 | 1,086 (99.9) | 1,110 (99.9) | > 0.999 | ||
| P2Y12 receptor inhibitor | ||||||||
| Clopidogrel | 351 (86.0) | 338 (87.3) | 0.661 | 798 (73.0) | 824 (74.2) | 0.583 | ||
| Prasugrel | 5 (1.2) | 4 (1.0) | > 0.999 | 57 (5.2) | 63 (5.7) | 0.729 | ||
| Ticagrelor | 51 (12.5) | 45 (11.6) | 0.788 | 232 (21.3) | 224 (20.4) | 0.495 | ||
| Statin | 385 (94.4) | 370 (95.6) | 0.522 | 1,031 (94.8) | 1,038 (93.5) | 0.213 | ||
| Angiotensin-converting enzyme inhibitor | 69 (17.0) | 66 (17.1) | > 0.999 | 202 (18.6) | 190 (17.1) | 0.394 | ||
| Angiotensin receptor inhibitor | 178 (43.8) | 147 (38.0) | 0.109 | 423 (39.0) | 413 (37.2) | 0.435 | ||
| β-Blocker | 219 (53.8) | 212 (54.8) | 0.839 | 576 (53.0) | 571 (51.5) | 0.508 | ||
Values are presented as number (%) or mean ± standard deviation.